Reducing Biologic Costs in Psoriasis & Eczema Management
Psoriasis and eczema are driving billions in annual pharmacy costs, largely due to the growing use of biologics. With costs expected to rise further by 2030, health plans and employers need a new approach.
Key Highlights
The Evidence
A March 2024 review in Frontiers in Pharmacology found 59% of patients maintained dose reduction for one year, with 69% sustaining it for two — and 80% of relapsed patients regained full response after resuming their prior dose, with no difference in quality of life versus standard dosing.
The Missing Piece
Biologics make up just 2% of U.S. prescriptions by volume but drive 37% of net drug spending, with combined psoriasis and eczema biologic spend projected to reach $50 billion within the next few years. Despite this, no current U.S. dermatology society guidelines address when or how to reduce treatment once a patient achieves remission.
Proven Results
Through Zest Health's value-based model, more than half of enrolled patients have shifted off high-cost biologics, 83% report improved quality of life, and 91% say their experience with Zest was better than their previous dermatology care.
Our latest report examines the true cost of biologic therapy in psoriasis and eczema care, from a $50 billion spending trajectory to the structural gaps keeping patients on high-cost treatment longer than necessary. The evidence is clear: for many patients in sustained remission, structured dose reduction can be safe, effective, and clinically appropriate. This creates an opportunity to lower total cost of care without compromising outcomes for our payer partners.
Let's work together
Partner with Zest Health to implement smarter, more cost-effective psoriasis and eczema care for your workforce, members, or clients. We're here to help you make a difference.
Get in touch